Glucotrack, Inc. (Nasdaq: GCTK) announced on September 14, 2026, that Paul V. Goode has resigned from the company's Board of Directors, effective immediately. The resignation was communicated in a letter to the Board, with the filing of the Current Report on Form 8-K occurring on September 18, 2026.
The filing states that the basis for Mr. Goode's departure is a conclusion that a potential conflict of interest exists between the Company and its subsidiary. This conflict relates to ongoing discussions regarding the implementation of duties, rights, and obligations under the merger agreement through which the Company completed its business combination with Lokahi Therapeutics, Inc.
As part of the standard disclosure process, the Company provided Mr. Goode with a copy of the statement regarding his resignation and offered him the opportunity to furnish a letter stating whether he agrees with the Company's disclosures or disagrees with them. A copy of Mr. Goode's resignation notice is filed as Exhibit 17.1 to the report.
